Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases

Aim: The objective of this study was to estimate and compare the cost-effectiveness of switching from a bivalent to a nonavalent human papillomavirus (HPV) vaccination program in Norway, incorporating all nonavalent vaccine-preventable HPV-related diseases and in the context of the latest cervical cancer screening program.Methods: A well-established dynamic transmission model of the natural history of HPV infection and disease was adapted to the Norwegian population. We determined the number of cases of HPV-related diseases and subsequent number of deaths, and the economic burden of HPV-related disease under the current standard of care conditions of bivalent and nonavalent vaccinations of girls and boys aged 12 years.Results: Compared to bivalent vaccination, nonavalent vaccination averted an additional 4,357 cases of HPV-related cancers, 421,925 cases of genital warts, and 543 cases of recurrent respiratory papillomatosis (RRP) over a 100-year time horizon. Nonavalent vaccination also averted an additional 1,044 deaths over the 100-year time horizon when compared with bivalent vaccination. Total costs were higher for the nonavalent strategy (10.5 billion NOK [€1.03 billion] vs. 9.3-9.4 billion NOK [€915-925 million] for bivalent vaccination). A switch to nonavalent vaccination had a higher vaccination cost (4.4 billion NOK [€433 million] vs. 2.7 billion NOK [€266 million] for bivalent vaccination) but resulted in a savings of 627-694 million NOK [€62-68 million] in treatment costs. A switch to nonavalent vaccination demonstrated an incremental cost-effectiveness ratio of 102,500 NOK (€10,086) per QALY versus bivalent vaccination.Conclusions: Using a model that incorporated the full range of HPV-related diseases, and the latest cervical cancer screening practices, we found that switching from bivalent to nonavalent vaccination would be considered cost-effective in Norway.

[1]  Jane J. Kim,et al.  Switching clinic‐based cervical cancer screening programs to human papillomavirus self‐sampling: A cost‐effectiveness analysis of vaccinated and unvaccinated Norwegian women , 2021, International journal of cancer.

[2]  M. Stanley,et al.  Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. , 2021, Vaccine.

[3]  M. Nygård,et al.  Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis. , 2021, Preventive medicine.

[4]  E. Elbasha,et al.  Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States , 2021, Human vaccines & immunotherapeutics.

[5]  E. Elbasha,et al.  Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study , 2021, BMC Infectious Diseases.

[6]  K. Frederiksen,et al.  Age at first intercourse, number of partners and sexually transmitted infection prevalence among Danish, Norwegian and Swedish women: estimates and trends from nationally representative cross‐sectional surveys of more than 100 000 women , 2020, Acta obstetricia et gynecologica Scandinavica.

[7]  S. Kjaer,et al.  The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity. , 2019, Vaccine.

[8]  E. Weiderpass,et al.  An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway , 2019, PloS one.

[9]  I. Kristiansen,et al.  The healthcare costs of treating human papillomavirus-related cancers in Norway , 2019, BMC Cancer.

[10]  P. Magnus,et al.  Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway , 2018, The Journal of infectious diseases.

[11]  R. Hutubessy,et al.  Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination. , 2018, Vaccine.

[12]  M. Nygård,et al.  Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: a registry-based study in Norway , 2018, BMJ Open.

[13]  P. Jebsen,et al.  Human papillomavirus in oropharyngeal squamous cell carcinoma in South-Eastern Norway: prevalence, genotype, and survival , 2017, European Archives of Oto-Rhino-Laryngology.

[14]  J. Berkhof,et al.  Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands , 2017, The Journal of infectious diseases.

[15]  M. Plummer,et al.  Worldwide burden of cancer attributable to HPV by site, country and HPV type , 2017, International journal of cancer.

[16]  K. Hsu,et al.  Impact of HPV vaccination on anogenital warts and respiratory papillomatosis , 2016, Human vaccines & immunotherapeutics.

[17]  R. Meisal,et al.  Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: A nationwide cross-sectional study of three non-vaccinated birth cohorts , 2016, Papillomavirus research.

[18]  N. Muñoz,et al.  Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. , 2015, European journal of cancer.

[19]  E. Joura,et al.  From the monovalent to the nine-valent HPV vaccine. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  N. Muñoz,et al.  Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. , 2014, European journal of cancer.

[21]  M. Nygård,et al.  Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway. , 2014, The Journal of infectious diseases.

[22]  J. Dillner,et al.  Recurrent Respiratory Papillomatosis: HPV Genotypes and Risk of High-Grade Laryngeal Neoplasia , 2014, PloS one.

[23]  A. Jemal,et al.  International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. , 2014, Oral oncology.

[24]  H. Cubie,et al.  Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types , 2014, British Journal of Cancer.

[25]  M. Nygård,et al.  Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys , 2014, PloS one.

[26]  J. Wilschut,et al.  Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account. , 2013, Vaccine.

[27]  S. Roze,et al.  A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France , 2013, Human vaccines & immunotherapeutics.

[28]  M. Postma,et al.  Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands , 2013, BMC Infectious Diseases.

[29]  M. Wagner,et al.  Systematic review of the incidence and prevalence of genital warts , 2013, BMC Infectious Diseases.

[30]  G. Baio,et al.  Economic Burden of Human Papillomavirus-Related Diseases in Italy , 2012, PloS one.

[31]  M. Plummer,et al.  Global burden of human papillomavirus and related diseases. , 2012, Vaccine.

[32]  S. Garland,et al.  A review of clinical trials of human papillomavirus prophylactic vaccines. , 2012, Vaccine.

[33]  Jane J. Kim,et al.  Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway , 2012, British Journal of Cancer.

[34]  E. Lynge,et al.  Introduction of human papillomavirus vaccination in Nordic countries. , 2012, Vaccine.

[35]  N. Muñoz,et al.  End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age , 2011, British Journal of Cancer.

[36]  Elamin H Elbasha,et al.  Impact of vaccinating boys and men against HPV in the United States. , 2010, Vaccine.

[37]  C. Wheeler,et al.  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial , 2010, BMJ : British Medical Journal.

[38]  M. Jit,et al.  Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. , 2010, Vaccine.

[39]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[40]  E. Dasbach,et al.  A Multi-Type HPV Transmission Model , 2008, Bulletin of mathematical biology.

[41]  F. Aubin,et al.  Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  EJ Dasbach,et al.  The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK , 2008, BJOG : an international journal of obstetrics and gynaecology.

[43]  P. Sparén,et al.  The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. , 2007, The Journal of infectious diseases.

[44]  Erik J. Dasbach,et al.  Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.

[45]  D. Gamerman,et al.  Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference, Second Edition , 2006 .

[46]  J. Redburn,et al.  Hysterectomy prevalence and adjusted cervical and uterine cancer rates in England and Wales , 2001, BJOG : an international journal of obstetrics and gynaecology.

[47]  R. Anderson,et al.  Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. , 1993, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[48]  N. Muñoz,et al.  Role of Human Papillomavirus in Penile Carcinomas Worldwide. , 2016, European urology.

[49]  M. Poljak,et al.  Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide , 2015, International journal of cancer.

[50]  R. Kessler,et al.  Self-Reported Population Health: An International Perspective based on EQ-5D , 2014, Springer Netherlands.